Lately, with the wide use of immune checkpoint inhibitors (ICIs) such as anti-programmed death-ligand-1 (PD-L1) and anti-programmed death-1 (PD-1) antibodies in advanced NSCLC, patients have had significantly improved quality of life and good prognosis, making immunotherapy (8–10) a new option for the treatment of resectable and potentially resectable NSCLC. Here, CD274 is linked to non-small cell lung carcinoma.